Dynavax Technologies Stock Today
| DVAX Stock | USD 13.62 0.02 0.15% |
PerformanceModest
| Odds Of DistressVery Low
|
Dynavax Technologies is trading at 13.62 as of the 21st of March 2025; that is 0.15% down since the beginning of the trading day. The stock's open price was 13.64. Dynavax Technologies has a very small chance of experiencing financial distress in the next few years but had a somewhat modest performance during the last 90 days. The performance scores are derived for the period starting the 21st of December 2024 and ending today, the 21st of March 2025. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 19th of February 2004 | Category Healthcare | Classification Health Care |
Dynavax Technologies Corporation, a biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. Dynavax Technologies Corporation was incorporated in 1996 and is headquartered in Emeryville, California. Dynavax Technologies operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on NASDAQ Exchange. The company has 124.07 M outstanding shares of which 20.04 M shares are currently shorted by private and institutional investors with about 10.6 trading days to cover. More on Dynavax Technologies
Moving against Dynavax Stock
Dynavax Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| Business President | Riccardo Manetti | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Thematic Idea | Pharmaceutical Products (View all Themes) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, SP Small-Cap 600, NASDAQ Biotechnology, NASDAQ Composite Total, Pharmaceutical Products, Health Care, Biotechnology, Drug Manufacturers—Specialty & Generic, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsDynavax Technologies can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Dynavax Technologies' financial leverage. It provides some insight into what part of Dynavax Technologies' total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dynavax Technologies (DVAX) is traded on NASDAQ Exchange in USA. It is located in 2100 Powell Street, EmeryVille, CA, United States, 94608 and employs 405 people. Dynavax Technologies is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Mid-Cap' category with a current market capitalization of 1.69 B. Dynavax Technologies conducts business under Biotechnology sector and is part of Health Care industry. The entity has 124.07 M outstanding shares of which 20.04 M shares are currently shorted by private and institutional investors with about 10.6 trading days to cover.
Dynavax Technologies currently holds about 518.17 M in cash with 66.51 M of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.1.
Check Dynavax Technologies Probability Of Bankruptcy
Ownership AllocationThe majority of Dynavax Technologies outstanding shares are owned by other corporate entities. These outside corporations are usually referred to as non-private investors looking to obtain positions in Dynavax Technologies to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Dynavax Technologies. Please pay attention to any change in the institutional holdings of Dynavax Technologies as this could imply that something significant has changed or is about to change at the company.
Check Dynavax Ownership Details
Dynavax Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Renaissance Technologies Corp | 2024-12-31 | 2.4 M | |
| Blair William & Co | 2024-12-31 | 2.3 M | |
| D. E. Shaw & Co Lp | 2024-12-31 | 1.9 M | |
| Tang Capital Management Llc | 2024-12-31 | 1.9 M | |
| Amvescap Plc. | 2024-12-31 | 1.6 M | |
| Northern Trust Corp | 2024-12-31 | 1.5 M | |
| Mizuho Markets Americas Llc | 2024-12-31 | 1.4 M | |
| Fisher Asset Management, Llc | 2024-12-31 | 1.3 M | |
| Charles Schwab Investment Management Inc | 2024-12-31 | 1.2 M | |
| Blackrock Inc | 2024-12-31 | 21.2 M | |
| Deep Track Capital, Lp | 2024-12-31 | 17.8 M |
Dynavax Technologies Historical Income Statement
Dynavax Stock Against Markets
Dynavax Technologies Corporate Management
| David Novack | Sr. VP of Operations and Quality | Profile | |
| Eric Frings | Site VP | Profile | |
| Robert MD | Medical Development | Profile | |
| Donn Casale | Senior Officer | Profile | |
| Nicole Arndt | Sr Relations | Profile |
Additional Tools for Dynavax Stock Analysis
When running Dynavax Technologies' price analysis, check to measure Dynavax Technologies' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Dynavax Technologies is operating at the current time. Most of Dynavax Technologies' value examination focuses on studying past and present price action to predict the probability of Dynavax Technologies' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Dynavax Technologies' price. Additionally, you may evaluate how the addition of Dynavax Technologies to your portfolios can decrease your overall portfolio volatility.